Skip to Main Content
About this Publication
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
Pubmed ID
19638620 (View this publication on the PubMed website)
Blood. 2009 Sep; Volume 114 (Issue 13): Pages 2730-2

Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, Baris D, Conde B, Rothman N


Prediagnostic serum concentration of soluble CD30 (sCD30), a marker for chronic B-cell stimulation, has been associated with increased risk of developing AIDS-related non-Hodgkin lymphoma (NHL) in a recent study of HIV(+) patients. To investigate among healthy persons whether serum sCD30 is associated with NHL risk, we carried out a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. There was a strong dose-response relationship between prediagnostic sCD30 concentration and NHL risk among 234 cases and 234 individually matched controls (odds ratio [95% confidence interval] for second, third, and fourth quartiles vs first quartile: 1.4 [0.8-2.6], 2.2 [1.2-4.1], 4.1 [2.2-7.8]; P(trend) < .001), which persisted among cases diagnosed 6 to 10 years after providing a blood sample. Given that a similar relationship has been observed among HIV(+) patients, our findings suggest that chronic B-cell stimulation may be an important mechanism involved in B-cell lymphomagenesis among severely immunocompromised and healthy populations alike.

Related CDAS Studies
Related CDAS Projects